Q&A Genmab 2021-11-26

	26/11 15:33 af Jan Van de Winkel	Also in September, dose escalation data from the EPCOR NHL-1 study of epcoritamab, in development with AbbVie, was published in The Lancet. More recently, ASH announced abstracts accepted for presentation. We are very pleased that there will be multiple presentations of epcoritamab data, including preliminary results in CLL as well as data for epcoritamab in combination with R-CHOP, and in combination with Revlimid and Rituxan..
	26/11 15:32 af Jan Van de Winkel	In addition to the exciting approval, in collaboration with Seagen, we also have a broad clinical development program in place for tisotumab vedotin. Notably, data from the innovaTV 205 study, which combines tisotumab vedotin with other therapies and in earlier lines of cervical cancer, was presented during an oral session at ESMO in September..
	26/11 15:31 af Jan Van de Winkel	We achieved a major milestone in our journey during the third quarter with the FDA approval of tisotumab vedotin as TIVDAK. There are now five products on the market that incorporate our innovation and for the first time we, in collaboration with our partner on TIVDAK, Seagen, are in a position to bring our own medicine to patients..
	26/11 15:31 af Jan Van de Winkel	Development highlights:..
	26/11 15:31 af Helge Larsen/PI-redaktør	Can you give us the financial highlights and the key achievements in Q3
	26/11 15:31 af Jan Van de Winkel	Hello all, Thank you for inviting us once more to chat with you all. We look forward to an exciting discussion with plenty of clever questions..
	26/11 15:30 af Helge Larsen/PI-redaktør	Good afternoon Jan van de Winkel. Welcome to Q&A here on ProInvestor.com. We are very happy to have you back here and ready to answer questions from our investors.
	26/11 15:30 af Jan Van de Winkel	Hello, yes we are online and ready for today's session.
	26/11 15:28 af Helge Larsen/PI-redaktør	Hi Jan van de Winkel. Are you online?
	26/11 13:32 af Helge Larsen/PI-redaktør	Q&A starter i dag kl. 14,30.